Know Cancer

forgot password

An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway

Phase 2
18 Years
Open (Enrolling)
Non-small Cell Lung Cancer

Thank you

Trial Information

An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway

Inclusion Criteria:

- Histologically confirmed NSCLC with activated PI3K pathway

- Progressive disease after prior systemic antineoplastic treatment(s) for advanced

- Archival or fresh tumor biopsy must be available for profiling

- Measurable and/or non-measurable disease as per RECIST 1.1 criteria

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

- Adequate organ function as assessed by laboratory tests

Exclusion Criteria:

- Patient has received previous treatment with PI3K inhibitors

- Patient with squamous NSCLC has received more than one line of chemotherapy
treatment for metastatic disease; patient with non-squamous NSCLC has received more
than two lines of systemic antineoplastic treatment for metastatic disease

- Uncontrolled or symptomatic CNS metastases

- Concurrent use of any other approved or investigational antineoplastic agent

- Radiotherapy ≤ 28 days prior to starting study drug

- Major surgery within 28 days prior to starting study drug

- History of clinically significant cardiac dysfunction, mood disorders, or poorly
controlled diabetes mellitus

- Current treatment with medication that has a known risk to prolong the QT interval or
inducing Torsades de Pointes

- Impairment of gastrointestinal (GI) function

- Chronic treatment with steroids or another immunosuppressive agent.

- Concurrent severe and/or uncontrolled medical condition

- Currently receiving Warfarin or another coumarin derivative

- Known history of HIV infection

- Sensory neuropathy with functional impairment (CTC grade 2 neuropathy, regardless of

- Pregnancy, lactation, or breastfeeding

- Woman of child-bearing potential

Other protocol-defined inclusion/exclusion criteria may apply

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression Free Survival (PFS) as measured using RECIST 1.1

Outcome Time Frame:

Every 6 weeks

Safety Issue:


Principal Investigator

Novartis Pharmaceuticals

Investigator Role:

Study Director

Investigator Affiliation:

Novartis Pharmaceuticals


United States: Food and Drug Administration

Study ID:




Start Date:

May 2011

Completion Date:

February 2015

Related Keywords:

  • Non-Small Cell Lung Cancer
  • NSCLC,
  • PI3K
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



Northwest Cancer Specialists Vancouver Location Portland, Oregon  97210
US Oncology Central Monitoring Dallas, Texas  75246
Ironwood Cancer and Research Centers Ironwood Chandler, Arizona  85224
Highlands Oncology Group Dept of Highlands Oncology Grp Fayetteville, Arkansas  72703
Nevada Cancer Institute Dept. of Nevada Cancer (3) Las Vegas, Nevada  89135
Hematology Oncology Associates of Northern New Jersey PA DeptofHem-OncofNorthern NJ (2) Morristown, New Jersey  07962
Overlook Hospital - Carol G Simon Cancer Center Carol G Simon Summit, New Jersey  07901
Medical University of South Carolina MUSC Charleston, South Carolina  29425
Arizona Oncology Associates Tucson (Rudasill & La Cholla) Phoenix, Arizona  
Cedars Sinai Medical Center Dept.of Cedars-Sinai Med. Ctr. Los Angeles, California  90048
University of Kansas Cancer Center Univ of KS Kansas City, Kansas  66160
Kansas City Cancer Center KCCC - Southwest Overland Park, Kansas  66210
Virginia Oncology Associates VOA - Lake Wright (2) *see Various Departments*, Virginia  
Massachusetts General Hospital Mass General Boston, Massachusetts  02114
Mayo Clinic - Arizona Mayo Scottsdale AZ *see Various Departments*, Arizona  
University of Colorado Univ CO Aurora, Colorado  80045
Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer Greenwood Village, Colorado  
H. Lee Moffitt Cancer Center/University of South Florida H Lee Moffitt Tampa, Florida  33612
Emory University School of Medicine/Winship Cancer Institute Emory 2 Atlanta, Georgia  30322
University of Chicago Medical Center Unvi Chi Chicago, Illinois  60546
Rush University Medical Center SC Chicago, Illinois  60612
Indiana University Indiana Univ 2 Indianapolis, Indiana  46202
Horizon Oncology Center Horizon Onc Lafayette, Indiana  47905
Fallon Clinic at Worcester Medical Center Fallon Clinic Worcester Med Worcester, Massachusetts  01608
Wayne State University/Karmanos Cancer Institute Wayne St Karmanos Detroit, Michigan  48201
Mayo Clinic - Rochester Mayo - Roch. Rochester, Minnesota  55905
Washington University School Of Medicine-Siteman Cancer Ctr Wash Uni St. Louis, Missouri  63110
University of Nebraska Medical Center CBKM120D2201 Omaha, Nebraska  68198
The Center for Cancer and Hematologic Disease Dept. of the CCHD Cherry Hill, New Jersey  08003
Roswell Park Cancer Institute Rosewell Buffalo, New York  14263
Memorial Sloan Kettering Cancer Center Sloan Kettering New York, New York  10021
Duke University Medical Center Duke 2 Durham, North Carolina  27710
MetroHealth Medical Center Dept.ofMetroHealthMedCtr.(2) Cleveland, Ohio  44109-1998
University of Oklahoma Health Sciences Center Dept. of Oklahoma Univ. HSC Oklahoma City, Oklahoma  73104
Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt 2 Nashville, Tennessee  37212
Texas Oncology, P.A. Austin Location Dallas, Texas  75251
U of TX Southwestern Medical Center - SimmonsCompCancerCtr Clinical Research Office Dallas, Texas  75390-9151
MD Anderson Cancer Center/University of Texas UT/MD Houston, Texas  77030-4009
Cancer Therapy & Research Center / UT Health Science Center CTRC 2 San Antonio, Texas  78229
Oncology Hematology Associates of Southest Virginia Roanoke Loc Roanoke, Virginia  24014
University of Wisconsin Univ WIsc 2 Madison, Wisconsin  53792
Baylor College of Medicine Baylor Texas Oncology Dallas, Texas  75246
University of California at San Diego, Moores Cancer Ctr SC San Diego, California  92103
Georgia Regents University GHSU Augusta, Georgia  30912
University of Pittsburgh Medical Center SC-2 Pittsburgh, Pennsylvania  
University of Virginia Health Systems SC-1 Charlottesville, Virginia  22908-0334